Search
Search titles only
By:
Search titles only
By:
Home
Forums
New posts
Search forums
What's new
New posts
New profile posts
Latest activity
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
Search
Search titles only
By:
Search titles only
By:
New posts
Search forums
Menu
Install the app
Install
Reply to Thread
Guest, we'd love to know what you think about the forum! Take the
Diabetes Forum Survey 2024 »
Home
Forums
Diabetes Discussion
Type 1 Diabetes
Afrezza inhaled fast acting insulin
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Message
<blockquote data-quote="tim2000s" data-source="post: 802969" data-attributes="member: 30007"><p>Had an interesting chat with the research analyst that covers health and Sanofi in particular. This isn't something that anyone in equity research is paying much attention to. </p><p></p><p>Most consider Afrezza a niche product and there is real concern that the introduction of a growth agent in to the lungs will cause similar issues to Exubera. There is some surprise that nothing has been found yet. What surprised them more was that Sanofi have gone back into inhalable insulin.</p><p></p><p>I have a different theory on the tie up with MannKind. I wonder if, in the face of the new faster acting insulin aspart that Novo is currently undergoing clinical trials with, Sanofi have some kind of agreement to use the monomer based insulin that MannKind are creating in an injectable. This would provide them with a faster rapid insulin and may overcome what seem to be significant concerns relating to lung issues. All speculation of course.</p></blockquote><p></p>
[QUOTE="tim2000s, post: 802969, member: 30007"] Had an interesting chat with the research analyst that covers health and Sanofi in particular. This isn't something that anyone in equity research is paying much attention to. Most consider Afrezza a niche product and there is real concern that the introduction of a growth agent in to the lungs will cause similar issues to Exubera. There is some surprise that nothing has been found yet. What surprised them more was that Sanofi have gone back into inhalable insulin. I have a different theory on the tie up with MannKind. I wonder if, in the face of the new faster acting insulin aspart that Novo is currently undergoing clinical trials with, Sanofi have some kind of agreement to use the monomer based insulin that MannKind are creating in an injectable. This would provide them with a faster rapid insulin and may overcome what seem to be significant concerns relating to lung issues. All speculation of course. [/QUOTE]
Verification
Post Reply
Home
Forums
Diabetes Discussion
Type 1 Diabetes
Afrezza inhaled fast acting insulin
Top
Bottom
Find support, ask questions and share your experiences. Ad free.
Join the community »
This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies.
Accept
Learn More.…